Acrivon Therapeutics (ACRV) Competitors

$1.90 -0.01 (-0.26%)

As of 01:26 PM Eastern

ACRV vs. PALI, BCYC, ABEO, AKBA, and RZLT

Should you be buying Acrivon Therapeutics stock or one of its competitors? The main competitors of Acrivon Therapeutics include Palisade Bio (PALI), Bicycle Therapeutics (BCYC), Abeona Therapeutics (ABEO), Akebia Therapeutics (AKBA), and Rezolute (RZLT). These companies are all part of the "pharmaceutical products" industry.

How does Acrivon Therapeutics compare to Palisade Bio?

Palisade Bio (NASDAQ:PALI) and Acrivon Therapeutics (NASDAQ:ACRV) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, earnings, analyst recommendations and dividends.

Acrivon Therapeutics is trading at a lower price-to-earnings ratio than Palisade Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Palisade Bio	N/A	N/A	-$16.78M	-$2.12	N/A
Acrivon Therapeutics	N/A	N/A	-$77.90M	-$2.02	N/A

Palisade Bio's return on equity of -47.76% beat Acrivon Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Palisade Bio	N/A	-47.76%	-42.98%
Acrivon Therapeutics	N/A	-57.23%	-51.09%

11.8% of Palisade Bio shares are owned by institutional investors. Comparatively, 71.6% of Acrivon Therapeutics shares are owned by institutional investors. 0.1% of Palisade Bio shares are owned by insiders. Comparatively, 8.5% of Acrivon Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Palisade Bio presently has a consensus target price of $10.20, suggesting a potential upside of 427.13%. Acrivon Therapeutics has a consensus target price of $11.67, suggesting a potential upside of 512.42%. Given Acrivon Therapeutics' higher possible upside, analysts plainly believe Acrivon Therapeutics is more favorable than Palisade Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Palisade Bio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Acrivon Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Acrivon Therapeutics had 1 more articles in the media than Palisade Bio. MarketBeat recorded 4 mentions for Acrivon Therapeutics and 3 mentions for Palisade Bio. Acrivon Therapeutics' average media sentiment score of 0.72 beat Palisade Bio's score of 0.58 indicating that Acrivon Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Palisade Bio	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Acrivon Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Palisade Bio has a beta of 1.52, indicating that its share price is 52% more volatile than the broader market. Comparatively, Acrivon Therapeutics has a beta of 2.01, indicating that its share price is 101% more volatile than the broader market.

Summary

Palisade Bio and Acrivon Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Acrivon Therapeutics compare to Bicycle Therapeutics?

Bicycle Therapeutics (NASDAQ:BCYC) and Acrivon Therapeutics (NASDAQ:ACRV) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, valuation, media sentiment, earnings, analyst recommendations, profitability and risk.

In the previous week, Acrivon Therapeutics had 1 more articles in the media than Bicycle Therapeutics. MarketBeat recorded 4 mentions for Acrivon Therapeutics and 3 mentions for Bicycle Therapeutics. Bicycle Therapeutics' average media sentiment score of 1.06 beat Acrivon Therapeutics' score of 0.72 indicating that Bicycle Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bicycle Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Acrivon Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Bicycle Therapeutics presently has a consensus price target of $14.00, indicating a potential upside of 201.40%. Acrivon Therapeutics has a consensus price target of $11.67, indicating a potential upside of 512.42%. Given Acrivon Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Acrivon Therapeutics is more favorable than Bicycle Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bicycle Therapeutics	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44
Acrivon Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Acrivon Therapeutics has a net margin of 0.00% compared to Bicycle Therapeutics' net margin of -344.95%. Bicycle Therapeutics' return on equity of -35.74% beat Acrivon Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bicycle Therapeutics	-344.95%	-35.74%	-29.54%
Acrivon Therapeutics	N/A	-57.23%	-51.09%

Bicycle Therapeutics has a beta of 1.56, meaning that its stock price is 56% more volatile than the broader market. Comparatively, Acrivon Therapeutics has a beta of 2.01, meaning that its stock price is 101% more volatile than the broader market.

Acrivon Therapeutics has lower revenue, but higher earnings than Bicycle Therapeutics. Bicycle Therapeutics is trading at a lower price-to-earnings ratio than Acrivon Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bicycle Therapeutics	$72.86M	4.44	-$218.96M	-$3.15	N/A
Acrivon Therapeutics	N/A	N/A	-$77.90M	-$2.02	N/A

86.2% of Bicycle Therapeutics shares are held by institutional investors. Comparatively, 71.6% of Acrivon Therapeutics shares are held by institutional investors. 8.5% of Bicycle Therapeutics shares are held by insiders. Comparatively, 8.5% of Acrivon Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Acrivon Therapeutics beats Bicycle Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Acrivon Therapeutics compare to Abeona Therapeutics?

Acrivon Therapeutics (NASDAQ:ACRV) and Abeona Therapeutics (NASDAQ:ABEO) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, dividends, institutional ownership, profitability, valuation, analyst recommendations, media sentiment and risk.

Abeona Therapeutics has higher revenue and earnings than Acrivon Therapeutics. Acrivon Therapeutics is trading at a lower price-to-earnings ratio than Abeona Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acrivon Therapeutics	N/A	N/A	-$77.90M	-$2.02	N/A
Abeona Therapeutics	$5.82M	55.17	$71.18M	$1.03	5.48

71.6% of Acrivon Therapeutics shares are held by institutional investors. Comparatively, 80.6% of Abeona Therapeutics shares are held by institutional investors. 8.5% of Acrivon Therapeutics shares are held by company insiders. Comparatively, 5.4% of Abeona Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Acrivon Therapeutics' return on equity of -57.23% beat Abeona Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Acrivon Therapeutics	N/A	-57.23%	-51.09%
Abeona Therapeutics	N/A	-60.65%	-40.78%

Acrivon Therapeutics currently has a consensus price target of $11.67, suggesting a potential upside of 512.42%. Abeona Therapeutics has a consensus price target of $19.00, suggesting a potential upside of 236.58%. Given Acrivon Therapeutics' higher probable upside, equities analysts clearly believe Acrivon Therapeutics is more favorable than Abeona Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acrivon Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Abeona Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Acrivon Therapeutics has a beta of 2.01, meaning that its share price is 101% more volatile than the broader market. Comparatively, Abeona Therapeutics has a beta of 1.35, meaning that its share price is 35% more volatile than the broader market.

In the previous week, Abeona Therapeutics had 2 more articles in the media than Acrivon Therapeutics. MarketBeat recorded 6 mentions for Abeona Therapeutics and 4 mentions for Acrivon Therapeutics. Acrivon Therapeutics' average media sentiment score of 0.72 beat Abeona Therapeutics' score of 0.51 indicating that Acrivon Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Acrivon Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Abeona Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Abeona Therapeutics beats Acrivon Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Acrivon Therapeutics compare to Akebia Therapeutics?

Acrivon Therapeutics (NASDAQ:ACRV) and Akebia Therapeutics (NASDAQ:AKBA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, risk, earnings, profitability, analyst recommendations and valuation.

Acrivon Therapeutics presently has a consensus price target of $11.67, suggesting a potential upside of 512.42%. Akebia Therapeutics has a consensus price target of $4.67, suggesting a potential upside of 290.52%. Given Acrivon Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Acrivon Therapeutics is more favorable than Akebia Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acrivon Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Akebia Therapeutics	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

Akebia Therapeutics has higher revenue and earnings than Acrivon Therapeutics. Akebia Therapeutics is trading at a lower price-to-earnings ratio than Acrivon Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acrivon Therapeutics	N/A	N/A	-$77.90M	-$2.02	N/A
Akebia Therapeutics	$236.20M	1.36	-$5.34M	-$0.08	N/A

71.6% of Acrivon Therapeutics shares are owned by institutional investors. Comparatively, 33.9% of Akebia Therapeutics shares are owned by institutional investors. 8.5% of Acrivon Therapeutics shares are owned by company insiders. Comparatively, 4.3% of Akebia Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Acrivon Therapeutics has a beta of 2.01, meaning that its share price is 101% more volatile than the broader market. Comparatively, Akebia Therapeutics has a beta of 0.35, meaning that its share price is 65% less volatile than the broader market.

Acrivon Therapeutics has a net margin of 0.00% compared to Akebia Therapeutics' net margin of -8.83%. Acrivon Therapeutics' return on equity of -57.23% beat Akebia Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Acrivon Therapeutics	N/A	-57.23%	-51.09%
Akebia Therapeutics	-8.83%	-62.72%	-5.66%

In the previous week, Akebia Therapeutics had 21 more articles in the media than Acrivon Therapeutics. MarketBeat recorded 25 mentions for Akebia Therapeutics and 4 mentions for Acrivon Therapeutics. Acrivon Therapeutics' average media sentiment score of 0.72 beat Akebia Therapeutics' score of -0.18 indicating that Acrivon Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Acrivon Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Akebia Therapeutics	1 Very Positive mention(s)	4 Positive mention(s)	5 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

Acrivon Therapeutics beats Akebia Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Acrivon Therapeutics compare to Rezolute?

Acrivon Therapeutics (NASDAQ:ACRV) and Rezolute (NASDAQ:RZLT) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, dividends, valuation, analyst recommendations, institutional ownership, risk and profitability.

Acrivon Therapeutics has a beta of 2.01, indicating that its stock price is 101% more volatile than the broader market. Comparatively, Rezolute has a beta of 0.66, indicating that its stock price is 34% less volatile than the broader market.

In the previous week, Acrivon Therapeutics and Acrivon Therapeutics both had 4 articles in the media. Acrivon Therapeutics' average media sentiment score of 0.72 beat Rezolute's score of 0.58 indicating that Acrivon Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Acrivon Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rezolute	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Acrivon Therapeutics currently has a consensus target price of $11.67, indicating a potential upside of 512.42%. Rezolute has a consensus target price of $8.00, indicating a potential upside of 139.88%. Given Acrivon Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Acrivon Therapeutics is more favorable than Rezolute.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acrivon Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Rezolute	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45

71.6% of Acrivon Therapeutics shares are owned by institutional investors. Comparatively, 83.0% of Rezolute shares are owned by institutional investors. 8.5% of Acrivon Therapeutics shares are owned by company insiders. Comparatively, 14.8% of Rezolute shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Rezolute is trading at a lower price-to-earnings ratio than Acrivon Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acrivon Therapeutics	N/A	N/A	-$77.90M	-$2.02	N/A
Rezolute	N/A	N/A	-$74.41M	-$0.93	N/A

Acrivon Therapeutics' return on equity of -57.23% beat Rezolute's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Acrivon Therapeutics	N/A	-57.23%	-51.09%
Rezolute	N/A	-64.81%	-59.37%

Summary

Acrivon Therapeutics beats Rezolute on 7 of the 12 factors compared between the two stocks.

Get Acrivon Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ACRV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ACRV vs. The Competition

Export

Metric	Acrivon Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$81.53M	$3.02B	$6.28B	$12.04B
Dividend Yield	N/A	1.93%	2.78%	5.23%
P/E Ratio	-0.94	17.60	20.49	25.22
Price / Sales	N/A	269.81	544.52	74.60
Price / Cash	N/A	55.41	27.81	36.29
Price / Book	0.53	4.09	9.58	6.58
Net Income	-$77.90M	$72.19M	$3.55B	$333.40M
7 Day Performance	-8.41%	-1.73%	-0.82%	-0.99%
1 Month Performance	22.12%	2.59%	5.46%	7.15%
1 Year Performance	58.75%	43.20%	37.70%	34.19%

Acrivon Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ACRV Acrivon Therapeutics	3.0524 of 5 stars	$1.91 -0.3%	$11.67 +512.4%	+64.7%	$81.53M	N/A	N/A	58	Upcoming Earnings
PALI Palisade Bio	2.2374 of 5 stars	$1.93 -0.8%	$10.20 +429.9%	+167.4%	$322.29M	N/A	N/A	10
BCYC Bicycle Therapeutics	3.4117 of 5 stars	$4.62 -1.6%	$14.00 +202.8%	-43.6%	$321.71M	$72.86M	N/A	240	Positive News Analyst Downgrade
ABEO Abeona Therapeutics	2.7429 of 5 stars	$5.62 -4.2%	$19.00 +238.4%	+11.2%	$319.38M	$5.82M	5.45	90	News Coverage Upcoming Earnings
AKBA Akebia Therapeutics	2.276 of 5 stars	$1.20 +3.9%	$4.67 +290.5%	-54.9%	$317.89M	$236.20M	N/A	430	Trending News Earnings Report Analyst Downgrade Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ACRV) was last updated on 5/12/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Acrivon Therapeutics (ACRV) Competitors

ACRV vs. PALI, BCYC, ABEO, AKBA, and RZLT

How does Acrivon Therapeutics compare to Palisade Bio?

Summary

How does Acrivon Therapeutics compare to Bicycle Therapeutics?

Summary

How does Acrivon Therapeutics compare to Abeona Therapeutics?

Summary

How does Acrivon Therapeutics compare to Akebia Therapeutics?

Summary

How does Acrivon Therapeutics compare to Rezolute?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACRV vs. The Competition

Acrivon Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Acrivon Therapeutics (ACRV) Competitors

ACRV vs. PALI, BCYC, ABEO, AKBA, and RZLT

How does Acrivon Therapeutics compare to Palisade Bio?

Which has stronger earnings & valuation, PALI or ACRV?

Is PALI or ACRV more profitable?

Do institutionals & insiders have more ownership in PALI or ACRV?

Do analysts rate PALI or ACRV?

Does the media favor PALI or ACRV?

Which has more volatility and risk, PALI or ACRV?

Summary

How does Acrivon Therapeutics compare to Bicycle Therapeutics?

Does the media favor BCYC or ACRV?

Do analysts recommend BCYC or ACRV?

Is BCYC or ACRV more profitable?

Which has more risk & volatility, BCYC or ACRV?

Which has better earnings and valuation, BCYC or ACRV?

Do institutionals and insiders believe in BCYC or ACRV?

Summary

How does Acrivon Therapeutics compare to Abeona Therapeutics?

Which has higher valuation & earnings, ACRV or ABEO?

Do institutionals & insiders have more ownership in ACRV or ABEO?

Is ACRV or ABEO more profitable?

Do analysts recommend ACRV or ABEO?

Which has more volatility and risk, ACRV or ABEO?

Does the media prefer ACRV or ABEO?

Summary

How does Acrivon Therapeutics compare to Akebia Therapeutics?

Do analysts rate ACRV or AKBA?

Which has stronger earnings & valuation, ACRV or AKBA?

Do institutionals and insiders hold more shares of ACRV or AKBA?

Which has more volatility and risk, ACRV or AKBA?

Is ACRV or AKBA more profitable?

Does the media favor ACRV or AKBA?

Summary

How does Acrivon Therapeutics compare to Rezolute?

Which has more risk and volatility, ACRV or RZLT?

Does the media favor ACRV or RZLT?

Do analysts rate ACRV or RZLT?

Do insiders & institutionals hold more shares of ACRV or RZLT?

Which has stronger earnings and valuation, ACRV or RZLT?

Is ACRV or RZLT more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACRV vs. The Competition

Acrivon Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools